Case StudY 1

Immune Design and Sanofi Immuno-Allergy

The license agreement signed between Immune Design and Sanofi to use Immune Design’s GLAASTM discovery platform in August 2014 is an example of SGBV achieving its strategic mandate and highlights SGBV as a preferred strategic investor for early stage companies.

Immune Design, a clinical-stage immunotherapy company, approached SGBV for its Series C financing in 2013. As part of the SGBV diligence process as a strategic investor, three groups within Sanofi, including the Immuno-Allergy team, engaged in considering the early stage opportunity. With strong internal support from these groups, SGBV joined top tier venture investors (The Column Group, Topspin Partners, Versant Ventures, Alta Partners, Osage Venture Partners and Proquest Investments) and invested in Immune Design in October 2013.

Subsequently, the company initiated a number of Phase I clinical trials and successfully completed an IPO (NASDAQ:IMDZ) to which Sanofi also participated. Facilitated by SGBV’s relationship-building as an investor, the Sanofi Immuno-Allergy team and the Immune Design team deepened interactions. In August 2014, the thoughtful relationship materialized with the execution of a license agreement between Immune Design and Sanofi to develop new therapeutics to treat food allergies using Immune Design’s GLAASTM discovery platform (press release). 

Your involvement as an investor and foresight as to the synergies between both groups have helped to achieve this important collaboration around the GLAASTM technology,” said Carlos Paya, President & CEO of Immune Design.

This agreement highlights SGBV as a preferred strategic investor for early stage companies and illustrates an achievement of our strategic mandate for Sanofi and Genzyme.

 

 

CASE STUDY 2

Immune Design and Sanofi Pasteur

The collaboration agreement signed between Immune Design and Sanofi Pasteur to develop best in class Herpes Simplex Virus vaccines (HSV) is another example of SGBV achieving our strategic mandate and vision to be a preferred strategic investor for early stage companies.

Immune Design, a clinical-stage immunotherapy company, approached SGBV for its Series C financing in 2013. As part of the SGBV diligence process as a strategic investor, three groups within Sanofi, including the Sanofi Pasteur team, engaged in considering the early stage opportunity. With strong internal support from these groups, SGBV joined top tier venture investors (The Column Group, Topspin Partners, Versant Ventures, Alta Partners, Osage Venture Partners and Proquest Investments) and invested in Immune Design in October 2013.

Subsequently, the company initiated a number of Phase I clinical trials and successfully completed an IPO (NASDAQ:IMDZ) to which Sanofi also participated. Facilitated by SGBV’s relationship-building as an investor, the Sanofi Pasteur team and the Immune Design team deepened their discussions. In October 2014, a collaboration agreement was signed between Immune Design and Sanofi to develop first in class HSV vaccines (press release). 

Building on our relationship with SGBV and subsequently the Sanofi Allergy team, we entered into discussions with Sanofi Pasteur, for another collaboration. We are now delighted to initiate this second collaboration with Sanofi to develop breakthrough products for patients,” said Carlos Paya, President & CEO of Immune Design.